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Objective(s): Diversity among health care providers is felt to be an
important component in addressing health care disparities and may help
improve patient communication. Caucasian men have historically repre-
sented vascular surgery (VS). We hypothesized that the 5-year integrated VS
residency paradigm might foster increased diversity.
Table. Applicants in vascular surgery training
% Independent (52) % Integrated (05)
Year Female Cauc Black Asian
Nat
Am Other
No
resp Female Cauc Black Asian
Nat
Am Other
No
resp
2007 15.8 54.2 5.2 25.2 0.0 4.5 11.0 0 83.3 0.0 0.0 0.0 16.7 0.0
2008 18.3 60.0 6.9 23.1 0.8 2.3 6.9 16.1 41.2 5.3 28.1 0.0 13.2 12.3
2009 19.5 63.7 4.8 15.3 0.0 4.0 12.1 22.1 39.6 5.8 24.0 0.0 11.0 19.5
2010 26.3 53.8 6.7 23.5 0.0 3.4 12.6 20.3 38.9 9.7 28.3 0.9 8.3 14.0
2011 27.1 53.5 3.1 29.4 0.7 4.6 11.6 22.9 54.1 1.9 18.5 0.6 8.2 26.1
First year residents in integrated vascular
residency First year fellows in vascular surgery
# Female # Male
% Female in PGY
1 year # Female # Male
% Female in first
year fellowship
2007 0 6 0% 15 104 13%
2008 3 11 21% 16 99 14%
2009 5 17 23% 18 99 15%
2010 9 18 33% 14 109 13%
2011 17 12 59% 20 94 18%
Methods: Applicant sex and race status listed on the Electronic Resi-
dent Application System (ERAS) from 2007 to 2011 was evaluated on all
applications to integrated (5-year) VS residencies and fellowships (2 year).
Sex data were available for all of VS Accredited Council for Graduate
Medical Education (ACGME) integrated residencies and fellowships. VS
training programs were also reviewed to determine diversity of program
directors and faculty.
Results: Female applicants to VS integrated programs increased 20-
fold during the 5-year study period, from 0 (0%) in 2007 to 69 (22.9%) in
2011, compared with a 1.7-fold increase in fellowship applicants. African
American applicants to integrated programs during the study period ranged
from 0% to 9.7% and Asian applicants from 0% to 28.3% (Table). There were
no women (0%) in the 2007 integrated intern class and 17 (59%) in the 2011
postgraduate year 1 class, compared with 15 (13%) and 20 (18%), respec-
tively, in the fellowships. Of 32 integrated VS programs in 2010, three
(9.4%) program directors were women, one (3.1%) was Asian, and 22
(68.7%) were Caucasian men. Of the 101 VS fellowship program directors,
seven (6.9%) were women, six (5.9%) were Asian, and 74 (73.2%) were
Caucasian men. One or more female VSs were on staff at 20 (62.5%) of the
VS divisions that had integrated training programs.
Conclusions: Redesigning training in VS appears to appeal to women,
with less effect on race. There remains room to increase diversity among
trainees, program directors, and faculty in VS training programs.
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Objective(s): The Belgian-Italian Trial Investigating Abbott Vascular
Vascular Iliac Stents in the Treatment of TASC A, B, C and D Iliac Lesions
(BRAVISSIMO) study is a prospective, nonrandomized, multicenter trial,
conducted at 12 Belgian hospitals and 11 Italian hospitals. The objective is
to evaluate the long-term (24-month) outcome of the self-expanding nitinol
Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite
(Abbott Vascular) stent in TransAtlantic InterSociety Concensus (TASC) A
and B and TASC C and D iliac lesions. A separate analysis of both patient
populations is performed.
Methods: Primary study end point is primary patency at 12 months,
defined as a target lesion without a hemodynamically significant stenosis
(50%, systolic velocity ratio 2.0) on duplex ultrasound imaging and
without target lesion revascularization (TLR) 12 months. The study
included 325 patients, of which 190 presented with TASCA or B lesions and
135 with TASC C or D lesions. Analysis is performed comparing the results
of the TASC A/B cohort with the results of the TASC C/D cohort.
Results: The study included 131 patients with TASC A, 59 with TASC
B, 54 with TASC C, and 82 with TASC D aortoiliac lesions. Demographic
data were comparable for all TASC patient groups. Of the TASC A patients,
85 received Omnilink Elite stents, 45 received Absolute Pro stents, and one
received both stents. Of the TASC B patients, 24 received Omnilink Elite
stents, 24 received Absolute Pro stents, and mixed stent use was reported in
two patients. In the TASC C group, 14 patients were treated with Onmilink
Elite, 34 with Absolute Pro, and six with both stents. Of the TASC D
patients, 29 received the Omnilink Elite, 35 received the Absolute Pro, and
18 received both. The 12-month primary patency rates were uniformly high,
without statistically significant differences among TASC groups: A, 94%; B,
96%; C, 91%; and D, 88%. Stratified by stent use, 12-month primary patency
rates were 96% for self-expanding stents, 90% for balloon-expandable stents,
and 84% for the 27 patients treated with both types (P  .03).
Conclusion: Primary endovascular treatment of symptomatic iliac
artery occlusive disease produces 12-month patency 88% irrespective of
TASC classification. On the basis of these findings, endovascular therapy
should be considered the treatment of choice for this condition; primary
aortofemoral bypass is no longer indicated for isolated iliac artery occlusive
disease.
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Objective(s):During the past decade, the treatment of popliteal aneu-
rysms has evolved at our institution from the sole operative intervention
during the initial part of the study period, to combined surgical and
endovascular treatment, and finally, to endovascular-centered management
in more recent years. Outcomes among treatment modalities for popliteal
aneurysms were assessed.
Methods: This is a retrospective review of all patients with popliteal
aneurysms treated at our institution from 2001 to 2011. Data collection
included the indication for intervention, treatment details, interventional
patency, limb salvage, perioperative outcome, and long-term survival.
Results: During this period, 88 aneurysms were treated in 72 patients.
Indications for intervention included 47 (53%)with symptomatic presentations,
and 41 (47%) were asymptomatic. Treatment included endovascular exclusion
in 24, surgical repair in 63 (14 posterior approach and 49medial approach with
bypass and exclusion), and primary amputation in one patient. Nine aneurysms
(10.2%) received catheter-directed thrombolysis (Fig). Demographics were
similar between the two treatment cohorts, except for age, with endovascular
stenting patients significantly older (76.0 vs 66.0 years, P  .002). The mean
length of stay was 3.9 vs 9.5 days (P .001), favoring endovascular treatment.
Therewere no perioperative (30-day) deaths in the endovascular group and one
death in the surgical cohort. The mean patency follow-up was 18.5 vs 28.3
months. Primary patency did not differ between endovascular and surgically
treated patients at 1 year (92.3% vs 83.3%,P .26) and3 years (61.5% vs 77.8%,
P  .89). No limbs were lost in the endovascular group during the follow-up
period of 22.4months.One late limb loss occurred in the surgical cohort (mean
follow-up, 29.2 months). The long-term survival rate was 65% in the endovas-
cular patients (mean follow up, 33.9months) and 80.8% in the surgical patients
(mean follow up, 42.9 months, P .22).
Conclusions: Endovascular treatment of popliteal aneurysms provides
similar short-term patency to that of the traditional gold standard approach
Fig.
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